{"type":"profile","id":"profile=medica2026.3076901","exhSeoId":"XtAixO2KQYuM4zPQaG4N3w","name":"ADmit Therapeutics SL","email":"info@admit-therapeutics.com","getInTouchEmail":"info@admit-therapeutics.com","profileAddress":{"address":["Ctra. Laurea Miro 408-410"],"city":"Sant Feliu de Llobregat (Barcelona)","zip":"08980","country":"Spain","countryCode":"ES"},"phone":{"phone":"+34 93 1088001"},"links":[{"id":"link=b9K2sxIDRkqWRzRzJ5shXQ","type":"link","link":"https://www.admit-therapeutics.com","parentType":"profile","order":1,"visibleInLang":["en","de"]}],"media":[],"locations":[{"areaId":"01","area":"Hall 1","stand":"D33"}],"location":"Hall 1 / D33","locationIsVirtual":false,"events":[{"key":"medica2026","label":"MEDICA 2026"}],"eventIcons":[{"label":"MEDICA 2026","src":"https://www.medica.de/vis-content/event-medica2026/all-exh/Event-0mOSbpheSRej6t2ZLcI1AA.png"}],"eventMap":"https://iahapla02.messe-duesseldorf.de/en/2dexgroundV2/medica2026/3076901.svg","areaMap":"https://iahapla02.messe-duesseldorf.de/en/3dhallV2/medica2026/01/3076901.svg","areaId":"01","premium":false,"exhIsLead":false,"logoUploadedByPubimport":false,"tags":[],"xtags":[],"socialMedia":[{"title":"LinkedIn","link":"https://www.linkedin.com/company/admit-therapeutics/home/","network":"linkedin","standardDomain":"https://www.linkedin.com/"}],"synonyms":[],"text":"<p>ADmit Therapeutics** is a biotech company founded in Barcelona as a spin-off of the Bellvitge Biomedical Research Institute (IDIBELL). The company specializes in early diagnostic and prognostic solutions for neurodegenerative conditions, focusing primarily on Alzheimer&#8217;s disease.</p><p><br></p><p>ADmit Therapeutics developed the MAP-AD® test, a proprietary, non-invasive technology that uses blood samples to analyze epigenetic biomarkers—specifically mitochondrial DNA methylation patterns—combined with machine learning algorithms. This novel mechanism enables healthcare providers to predict progression to Alzheimer's dementia in patients with mild cognitive impairment well before severe symptoms occur.</p><p><br></p><p>By advancing precision medicine and transforming clinical patient management, ADmit Therapeutics aims to streamline early interventions and optimize patient selection for pharmaceutical clinical trials worldwide.</p>","pdfs":[{"id":"paper=rztZRw3VQtSGcE91y4pLLQ","type":"paper","title":"Flyer_MAP_AD","source":"https://www.medica.de/vis-content/event-medica2026/exh-medica2026.3076901/MEDICA-2026-ADmit-Therapeutics-SL-Paper-medica2026.3076901-ZMdbvmu1TdqLMK82aEQTbw.pdf","parentType":"profile","fileName":"Flyer_MAP_AD.pdf","order":1,"visibleInLang":["en","de"]},{"id":"paper=E33or1u8Shi3zwRbEnl62w","type":"paper","title":"MAP-AD-Pioneering-Precision-Medicine-and-Prognosis-in-Alzheimers-Disease_Onepager","source":"https://www.medica.de/vis-content/event-medica2026/exh-medica2026.3076901/MEDICA-2026-ADmit-Therapeutics-SL-Paper-medica2026.3076901-QDfAUKw7ThmdP7bPNyVDkA.pdf","parentType":"profile","fileName":"MAP-AD-Pioneering-Precision-Medicine-and-Prognosis-in-Alzheimers-Disease_Onepager.pdf","order":2,"visibleInLang":["en","de"]}],"tol":[],"categories":[{"id":"prod=medica2026.01.02.02.02","label":"Next-generation sequencing (NGS)","catalogIndex":"01.02.02.02","eventIcons":[{"key":"medica2026","small":"https://www.medica.de/vis-content/event-medica2026/all-exh/Event-SzHinHZFRDix2fwVNyP4ag.png","tiny":"https://www.medica.de/vis-content/event-medica2026/all-exh/Event-0mOSbpheSRej6t2ZLcI1AA.png","label":"MEDICA 2026"}],"productList":[{"id":"prodinfo=JSQA3FZFRJK3Lvk5Jlvgwg","label":"MAP-AD-Pioneering-Precision-Medicine-and-Prognosis-in-Alzheimers-Disease"}],"hierarchy":[{"id":"01","label":"Clinical Diagnostics & Therapeutic Technologies"},{"id":"01.02","label":"Laboratory, IVD & Diagnostics"},{"id":"01.02.02","label":"Molecular diagnostics & genomics"},{"id":"01.02.02.02","label":"Next-generation sequencing (NGS)"}]}],"write":false,"lastModified":"2026-11-03T22:22:06Z","tagsAreEditable":false,"xtagsAreEditable":false,"isGetInTouchAllowed":false}